Pregnancy is a considerable undertaking for women with sickle cell disease as it is associated with increased maternal and fetal mortality and morbidity.' Contraceptive use is therefore an important part of health care for these women; of the widely used methods of contraception, however, there are uncertainties over the safety of two of them. The combined oral contraceptive pill has been reportedly associated with increased thrombotic risks,234 and several authors have cautioned against the use of the intrauterine device.25 Sickle cell disease is listed in the manufacturers' data sheets in the United Kingdom as a contraindication to the use of many combined oral contraceptive and postcoital contraceptive pills. Because of the severe risks of pregnancy in these women, however, it has been suggested that sickle cell disease should only be a relative contraindication to the use of combined oral contraception. 6 Sickle cell disease has been considered not to be a contraindication to the use of injectable progestogens (for example, medroxyprogesterone acetate) or the progestogen only pill, and they are widely used in Jamaica.7
There is a lack of information on the use of contraceptives among women with sickle cell disease in the United Kingdom, and this is felt to mirror the confused state of family planning advice provided for these women. We investigated use of contraceptives and complications in women with sickle haemoglobinopathies. We also assessed the effect of pregnancy counselling and the understanding of inheritance patterns and techniques of antenatal diagnosis.
Subjects and methods
A detailed questionnaire was administered by confidential personal interview by a research midwife (CL) to all women with sickle cell disease known to the haematology departments and sickle cell centres of north London. Each woman was visited at her local hospital or at home after the object of the survey had been explained by the woman's haematologist or sickle cell counsellor. Each woman was asked about her menstrual history, obstetric and gynaecological history, and current and past contraceptive use and problems. The same women were asked firstly, whether anyone had advised them against pregnancy and if so who and had this affected their plans; secondly, if their partner carried sickle cell trait what was the risk of producing a child with sickle cell anaemia; and thirdly, if they were aware of antenatal diagnosis-for example, chorionic villus sampling, amniocentesis, or cord blood sampling by ultrasound guidance.
Because of the confidential and anonymous nature of the interviews it was not possible to corroborate the women's reports by reference to their hospital medical records. All symptoms and complications given are thus taken from the accounts of the women themselves. Ethical committee approval was obtained from all participating hospitals. Every effort was made to conduct the survey in as culturally sensitive a manner as possible with the hope of avoiding previously notorious connotations raised by the suggestion of fertility control in these ethnic groups.
Results
A total of 164 women were asked to take part in this study and eight refused. Forty The table shows the numbers of women using the combined contraceptive pill, the progestogen only pill, the intrauterine device, and injectable progestogens (for example, Depo-Provera) with the reported side effects. In those women using the combined contraceptive pill four complained of increased crises (three had homozygous sickle cell disease and one had sickle thalassaemia), and two women reported deep vein thrombosis. The We found that 45% of all women had used the combined contraceptive pill at some time, with 19% having used the intrauterine device. This is similar to results from North America where it was found that 39% used the combined contraceptive pill and 15-4% used the intrauterine device.'2 Most authors have now concluded that the intrauterine device is safe in women with sickle cell disease3 7 13; the theoretical risk of endometritis and tube ovarian abscess with the added possibility of provoking sickling crises, which has been cited by some workers,2 has not been proved. There are more data on the use of injectable progestogensfor example, Depo-Provera-and several authors have reported on its safety.4'7 '4 Of the 26 women in our series who had used injectable progestogens there were no reports of serious side effects.
Our finding of two women with a history of a deep vein thrombosis when taking the contraceptive pill is disturbing. Both gave a history to the researcher of admission to hospital and anticoagulation, but we were unable to verify this from hospital records because of the confidential nature of the study. Reports 16 There have been two case reports of women with sickle cell trait who had thromboembolism while taking the combined contraceptive pill.7 18 No convincing case is made, however, to justify the implication that their sickle cell trait had any relevance. There has also been a report of two women with sickle cell haemoglobin C disease who had pulmonary infarction while taking the combined contraceptive pill.'9 The report does not in fact provide evidence, however, to justify the conclusion that this was a thromboembolic infarction as opposed to pulmonary sickling or infection, or both. All these women were taking high dose pills, and we can find no reports of thrombosis on modem low dose pills. We feel that such case reports may have unwittingly generated the current widespread confusion among practitioners on this issue.
We also found that four women had increased crises while on the contraceptive pill, and there are few other reports of this. One 10 year study of 71 patients with sickle cell anaemia who were on contraceptives containing oestrogen indicated that there were no adverse effects on the clinical course of these women with only one having possibly related sickling crises.'6 REPRODUCTIVE 
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The high rate of unplanned pregnancy in this group of women would suggest that the use of contraceptives is far from adequate. Our finding that one third have been advised against pregnancy contrasts with the evident lack of effective advice on contraception shown by the rate of unplanned pregnancy of 64-2%. This is higher than that reported by a previous similar study, in which the rate was 38%./o2 A weakness of our study is acknowledged in the lack of a control population to assess rates of unplanned pregnancy in the general population; a previous report, however, suggests it is around 32%.2°Many of these unplanned pregnancies will be terminated; in our study the figure of 19% agrees with evidence to suggest that one in five pregnancies are terminated in the United Kingdom.
Conclusion
The confused medical awareness of which contraceptive methods are appropriate may partly explain why advice to women with sickle cell disease is often lacking. We cannot exclude a possible risk of crises and thrombotic episodes with the use of the combined contraceptive pill. Despite this, we do not consider it to be contraindicated in this group of women as any complications should be balanced against the substantial risks of pregnancy. We feel that all methods of contraception may be considered in women with sickle haemoglobinopathies, though with appropriate caution. Pedestrian injuries are a leading cause of childhood mortality and disability. Over the past two decades in Britain child pedestrian death rates have fallen despite large increases in traffic volume. In this paper Roberts examines the likely reasons for this decline. He argues that neither prevention programmes nor improvements in medical care are a plausible explanation and that the decline is most likely the result of a substantial reduction in children's traffic exposure. He believes, however, that restricting children's traffic exposure exacerbates socioeconomic differentials in childhood mortality and denies children their right to mobility. Roberts is convinced that one answer is for British transport policy to be aimed at providing mobility equitably rather than struggling to meet the ever increasing demands ofcar travel.
Between 1980 and 1990 in England and Wales an average of 239 children were killed each year on the roads as pedestrians. For every death around 10 children required hospital admission for injuries.' Pedestrian injuries were among the leading causes of childhood admission to intensive care facilities.2 Between 60% and 80% of these children have severe head injuries and are likely to experience long term disability.'
With the more widespread recognition of the public health importance of child pedestrian injuries in recent years several epidemiological studies have been mounted aimed at identifying modifiable risk factors. These studies have used case-control or cohort methods in an attempt to identify the factors which place some children at high risk of pedestrian injury."6 However, an effective public health response to the problem of child pedestrian injury demands that a second aetiological issue should be addressed. This concerns the identification of determinants of the incidence, attempting to understand why child pedestrian death rates change over time. Answering this question is likely to be as important as identifying risk factors, because if the determinants of the incidence could be identified it might be possible to control them, with gains for the whole child population. 7 Over the past two decades child pedestrian death rates have fallen in many developed countries. In England and Wales between 1968 and 1987 the pedestrian mortality among children aged 0-4 years fell by 67%, and among children aged 5-14 years it fell by 39%.8 To gain an insight into why child pedestrian death rates have fallen changes in the potential determinants of the child pedestrian death rate must be considered.
Potential determinants ofchild pedestrian deaths
The determinants of incidence are most readily identified when their prevalence changes abruptly. For this reason the effect of traffic volume on child pedestrian mortality was most evident during the energy crisis, when an increase in the price of petrol had a measurable effect on the growth in traffic volume. In New Zealand government restrictions on car use in the aftermath of the energy crisis effectively arrested the growth in traffic volume for seven years, during which there was a 46-4% reduction in child pedestrian mortality.9 Before this the death rate had been increasing in parallel with increasing traffic volumes. That the rate fell, as opposed to levelling off in line with traffic volume, suggests that there were other processes operating, tending to reduce the mortality, but which became evident only when traffic
